NCT07094113 - AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

434

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

September 6, 2027

Study Completion Date

September 9, 2030

Conditions

KRAS Altered Advanced or Metastatic Solid Tumors

Interventions

DRUG

AMG 410

Administered as an oral tablet.

DRUG

Pembrolizumab

Administered as an intravenous (IV) infusion.

DRUG

Panitumumab

Administered as an IV infusion.

Trial Locations (4)

RECRUITING

Peter MacCallum Cancer Centre, Parkville

RECRUITING

Next Virginia, Fairfax

RECRUITING

Next Oncology, San Antonio

RECRUITING

City of Hope National Medical Center, Duarte